Oppenheimer Asset Management Inc. Sells 127 Shares of Eli Lilly and Company (NYSE:LLY)

Oppenheimer Asset Management Inc. lessened its position in Eli Lilly and Company (NYSE:LLY) by 0.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,263 shares of the company’s stock after selling 127 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Eli Lilly and Company were worth $34,785,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. China Universal Asset Management Co. Ltd. raised its holdings in Eli Lilly and Company by 19.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock worth $7,699,000 after purchasing an additional 1,620 shares in the last quarter. William Blair Investment Management LLC acquired a new stake in Eli Lilly and Company in the first quarter valued at approximately $1,540,000. D Orazio & Associates Inc. grew its holdings in Eli Lilly and Company by 2.5% in the first quarter. D Orazio & Associates Inc. now owns 1,936 shares of the company’s stock worth $1,506,000 after purchasing an additional 48 shares during the last quarter. TBH Global Asset Management LLC increased its position in shares of Eli Lilly and Company by 10.9% during the first quarter. TBH Global Asset Management LLC now owns 2,021 shares of the company’s stock worth $1,572,000 after purchasing an additional 199 shares in the last quarter. Finally, Kingsview Wealth Management LLC lifted its holdings in shares of Eli Lilly and Company by 2.9% during the 1st quarter. Kingsview Wealth Management LLC now owns 50,631 shares of the company’s stock valued at $39,389,000 after purchasing an additional 1,421 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $8.67 during trading hours on Wednesday, hitting $827.53. The company’s stock had a trading volume of 243,262 shares, compared to its average volume of 3,102,353. The business’s 50-day moving average is $891.02 and its two-hundred day moving average is $870.71. The company has a market capitalization of $785.59 billion, a PE ratio of 88.52, a PEG ratio of 3.15 and a beta of 0.43. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. Eli Lilly and Company has a 52-week low of $561.65 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. During the same quarter last year, the business posted $0.10 earnings per share. The business’s revenue was up 20.4% compared to the same quarter last year. As a group, research analysts anticipate that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.63%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Citigroup lifted their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Guggenheim boosted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target for the company. Finally, Barclays lowered their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Four analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,008.41.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.